This is the text extract for Tender of certain pharmaceuticals, browse documents here.

---

Level 14, Cigna House, 40 Mercer Street P O Box 10-254, Wellington

17 October 2003

NEW ZEALAND Phone 64 4 460 4990 Fax 64 4 460 4995

To:

DHB Hospital Pharmacies Medical groups and interested parties

CONSULTATION ON TENDER OF CERTAIN PHARMACEUTICALS FOR

RESPONSES DUE BY 5PM,

7 NOVEMBER 2003

In accordance with PHARMAC’s objective of securing for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided, PHARMAC is consulting on tendering for supply of certain pharmaceuticals to DHB Hospitals. These pharmaceuticals are appended to this letter entitled Schedule One. We seek comments on the approach outlined in the following pages, in particular the following: • the proposed process and timetable; • the actual or potential clinical implications of awarding Hospital Supply Status (as defined in Section H of the Pharmaceutical Schedule) to the pharmaceuticals listed in Schedule One; and • what the appropriate DV Limit for each product would be where a 0% DV Limit is considered clinically unacceptable. This document including the appendix is available on the PHARMAC website: www.pharmac.govt.nz. Additional hard copies can also be obtained by contacting PHARMAC. You can call us toll free on 0800 66 00 50 between the hours of 9am and 4pm weekdays. Background Since 1997 PHARMAC has been using the strategy of tendering for sole subsidised supply of community pharmaceuticals for a fixed period of time. Tendering has proven to be an effective way to encourage competition among suppliers of off patent pharmaceuticals. In 2002, the first tender for DHB hospital supply was issued with similar success to that achieved in the community. As in 2002, it is proposed that the community tender and hospital tender processes be run in unison, however the product list for each sector may be different. Key Aspects of Awarding a Tender: • The tender winning brand would be the only brand DHB hospitals could purchase (excluding any allowance for alternate brands under the agreed DV Limits) for

R31-2-0 #75102

---

approximately 2 years with an opportunity to extend the tender for an additional 12 months. From this tender process the Hospital Supply Status period will conclude on 30 June 2006 or 30 June 2007 (if the tender is extended). • No other brand of the pharmaceutical would be listed (or purchased) on Section H of the Pharmaceutical Schedule during the Tender period except as allowed under any DV Limits.

The Process The tender process is run annually and is structured as follows: Event September 2003 Consultation on proposed community product list with suppliers, medical groups and interested parties. Opportunity for suppliers to submit proposals that, if accepted, could prevent tendering.

Date

October 2003 November 2003 Late December 2003 Early March 2004 From April 2004 From August 2004

Consultation on proposed hospital product list with suppliers, medical groups and interested parties. Meeting of Tender Medical Evaluation Subcommittee of PTAC. Issuing of the Invitation to Tender 2003-04. Receipt of tender bids from suppliers to PHARMAC. Board decisions on tender winners announced. Hospital Supply Status and DV Limits apply to hospital tenders. Subsidy reductions to tender prices and consequent reference pricing for community tenders. Delisting of non-tender winning brands for community tenders. End of Hospital Supply Status (unless the tender is extended for an additional 12 months). Tender winning suppliers would continue to supply for at least three subsequent months. End of Hospital Supply Status (if the tender is extended for an additional 12 months). End of sole supply period for all products where a community tender is awarded in 2003-04 Tender. Tender winning suppliers would continue to supply for at least three subsequent months.

From November 2004 30 June 2006

30 June 2007

Tenders for Hospital Supply Status The pharmaceuticals listed in Schedule One are all proposed for tendering for Hospital Supply Status to DHB hospitals only. Contractual obligations for suppliers A copy of the draft contractual requirements which would form the clauses of the contract with successful suppliers in the 2003/04 Tender will be available for consultation in November 2003 on the PHARMAC website – www.pharmac.govt.nz – or by phoning PHARMAC. You can call free on 0800 66 00 50 between the hours of 9am and 4pm weekdays.

R31-2-0 #75102

---

Distribution of Consultation Documents Please note that this consultation letter has been widely distributed however should you consider that a particular person, group or agency should receive this and future tender documents please feel free to contact PHARMAC or forward this document yourself. Responses to consultation The closing date for responses to consultation is 5pm, 7 November 2003. All feedback received by this date will be considered by the Tender Medical Evaluation Sub-committee of PTAC prior to consideration by the PHARMAC Board. Please direct any queries you may have to Matthew matthew.perkins@pharmac.govt.nz; Ph: +64 4 9167 504) at PHARMAC. Perkins (email:

Yours sincerely

Sarah Schmitt Manager, Hospital Pharmaceuticals

R31-2-0 #75102

---

SCHEDULE ONE: POSSIBLE PRODUCTS FOR TENDER FOR SOLE SUPPLY Choice of products selected Schedule One lists the products for which we are consulting on tendering for supply to DHB Hospitals. PHARMAC welcomes any comments you may have with regard to the inclusion of these products in a tender for sole subsidised supply arrangements. Proposed tender products are listed alphabetically by chemical, form and strength (together forming a line item). Products that are known by PHARMAC to be on patent will not be included in the final tender list. The product list has been amended to aid in feedback for individual products. We have included space for you to suggest suitable DV Limits where you believe a limit other than 0% is necessary; space is also provided to enable brief justification for your recommendation. Hand-written comments are acceptable and you are welcome to make a more detailed written submission on any aspect of the proposed tender process and product list should you wish to.

R31-2-0 #75102

---

Chemical Name

Formulation Name

Proposed DV Limit

Suggested DV Limit

Product specific comments

Abacavir Sulphate Tab 300 mg Abciximab Inj 2 mg per ml, 5 ml Acetic Acid Soln 3% Soln 5% Acetylcholine Inj 10 mg per ml, 2 ml Acetylcysteine Inj 200 mg per ml, 10 ml Adenosine Inj 3 mg per ml, 2 ml Adrenaline Inj 1 in 1000, 1 ml Inj 1 mg per ml Albendazole Tab 200 mg Alfentanil Inj 0.5 mg per ml, 2 ml Alprostadil Inj 500 mcg per ml Amethocaine Gel 4% Minims 1% Amikacin Sulphate Inj 250 mg per ml, 2ml Aminocaproic Acid Inj 250 mg per ml, 20 ml Amiodarone Inj 50 mg per ml, 3 ml Amoxycillin Cap 250 mg Cap 500 mg Anagrelide Tab 0.5 mg Aprotinin Inj 10,000,000 iu per ml, 50 ml Aspaginase Inj 10,000 iu Aspirin Tab EC 100 mg Azithromycin Tab 500 mg Aztreonam Inj 1 g Baclofen Inj 2 mg per ml, 5 ml Barium Sulphate Enema 94%

0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%

Friday, 17 October 2003

Page 1

---

Chemical Name

Formulation Name

Proposed DV Limit

Suggested DV Limit

Product specific comments

Beclomethasone Dipropionate Aerosol inhaler, 250 mcg per dose, breath activated Benoxinate Minims 0.4% Benzalkonium with Panthenol Crm 500ug with 50 mg panthenol per g

0%

0% 0%

Betamethasone Sodium Phosphate with Betamethasone Acetate Inj 3.9 mg with betamethasone acetate 3 mg per 0% ml, 1ml Bisacodyl Suppos 10 mg Budesonide Powder for inhalation, 200 mcg per dose Powder for inhalation, 400 mcg per dose Buserelin Acetate Inj 1 mg per ml, 5.5 ml Caffeine Citrate 10 mg per ml, 2.5 ml Calciferol Tab 50,000 iu Calcitriol Cap 0.25 mcg Cap 0.5 mcg Calcium Carbonate Tab 1.25g Calcium Chloride Inj 10%, 10 ml Calcium Folinate Inj 50 mg Calcium Gluconate Inj 10%, 10 ml Calcium Polystyrene Sulphonate Powder Carbamazepine Oral liq 100 mg per 5 ml Tab 200 mg Carboplatin Inj 10 mg per ml, 15 ml Inj 10 mg per ml, 45 ml Carboprost Inj 250 mcg per ml Carvedilol Tab 6.25 mg Caspofungin Inj 5 mg per ml, 10 ml Cefaclor Monohydrate Cap 250 mg Cefamandole Inj 1 g 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%

Friday, 17 October 2003

Page 2

---

Chemical Name

Formulation Name

Proposed DV Limit

Suggested DV Limit

Product specific comments

Cefamandole Nafate Inj 500 mg Cefepime Inj 1 g Inj 2 g Inj 500 mg Cefotaxime Inj 1 g Cefotetan Inj 1 g Inj 2 g Cefoxitin Sodium Inj 1 g Cefpirome Inj 1 g Inj 2 g Charcoal 50 g per 300 ml Chloramphenicol Eye oint 1% Chlorhexidine Crm 1% Obstetric Soln 0.05% Soln 0.1% Soln 2% Soln 20% Chlorhexidine Gluconate Handrub 0.5% with ethanol 70% Soln 4% Chlorhexidine with Cetrimide Soln 0.015% with 0.15% cetrimide Chlorhexidine with Isopropyl Alcohol 0.5% in 70% alcohol Cidofovir Inj 75 mg per ml, 5 ml Cilazapril Tab 0.5 mg Tab 2.5 mg Tab 5 mg Ciprofoxacin Inj 2 mg per ml, 100 ml Oral liq 250 mg per 5 ml Oral liq 500 mg per 5 ml Cisplatin Inj 1 mg per ml, 50 ml Clarithromycin Inj 500 mg Tab 250 mg

0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%

Friday, 17 October 2003

Page 3

---

Chemical Name

Formulation Name

Proposed DV Limit

Suggested DV Limit

Product specific comments

Clindamycin Cap 150 mg Inj 140 mg per ml, 4 ml Clonidine Inj 150 mcg per ml, 1 ml Transdermal delivery system 2.5 mg, 100 mcg per day Clopidogrel Tab 75 mg Cocaine Soln 4% Codeine Phosphate Tab 30 mg Tab 60 mg Colistin Sulphomethate Inj 150 mg Co-trimoxazole Inj, 96 mg per ml, 5 ml Cyclizine Hydrochloride Tab 50 mg Cyclizine Lactate Inj 50 mg per ml, 1 ml Cyclopentolate Hydrochloride Eye drops 1% Cyclophosphamide Inj 1 g Cyproterone Acetate Inj 100 mg per ml, 3 ml Cytarabine 100 mg per ml, 10 ml 100 mg per ml, 20 ml 100 mg per ml, 5 ml Dacarbazine Inj 200 mg Dantrolene Inj 20 mg Daunorubicin Inj 5 mg per ml, 5 ml Desferrioxamine Inj 1 g Desferrioxamine Mesylate Inj 500 mg Desflurane Liq Desipramine Hydrochloride Tab 25 mg Desmopressin Inj 15 mcg per ml Inj 4 mcg per ml, 1 ml Oral liq 2 mcg per ml, 5 ml

0% 0% 0% 0%

0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%

Friday, 17 October 2003

Page 4

---

Chemical Name

Formulation Name

Proposed DV Limit

Suggested DV Limit

Product specific comments

Dexamethasone Tab 4 mg Dexamethasone Sodium Phosphate Inj 4 mg per ml, 1 ml Inj 4 mg per ml, 2 ml Dexamethasone with Framycetin and Gramcidin Ear/eye drops 500 ug with framycetin sulphate 5 mg and gramcidin 50 ug per ml Dextrose Inj 50%, 10 ml Dextrose with Electrolytes Soln with electrolytes Soln with electrolytes 1000 ml Diazepam Inj 5 mg per ml, 2 ml Tab 10 mg Tab 5 mg Dinoprostone Gel 1 mg Gel 2 mg Pessary 1 mg Pessary 2 mg Diphemanil Methylsulphate Powder 2% Dipyridamole Cap long acting 150 mg Docetaxel Inj 10 mg per ml, 2 ml Inj 10 mg per ml, 8 ml Docusate Sodium with Sennosides Tab 50 mg with total sennosides 8 mg Donepezil Hydrochloride Tab 5 mg Dopamine Inj 40 mg per ml, 5 ml Droperidol Inj 2.5 mg per ml, 1 ml Inj 5 mg per ml, 2 ml Efavirenz Cap 200 mg Tab 600 mg Ephedrine Inj 30 mg per ml Epirubicin Inj 2 mg per ml, 2 ml Inj 2 mg per ml, 25 ml Eptifibatide Inj 2 mg per ml, 10 ml Inj 750 ug per ml, 100 ml

0% 0% 0% 0%

0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%

Friday, 17 October 2003

Page 5

---

Chemical Name

Formulation Name

Proposed DV Limit

Suggested DV Limit

Product specific comments

Erythromycin Stearate Tab 250 mg Erythropoietin Inj 10,000 iu, pre-filled syringe Inj 2,000 iu, pre-filled syringe Inj 3,000 iu, pre-filled syringe Inj 4,000 iu, pre-filled syringe Inj 5,000 iu, pre-filled syringe Inj 6,000 iu, pre-filled syringe Erythropoietin Alpha Inj human recombinant 1,000 u pre-filled syringe Inj human recombinant 10,000 u, pre-filled syringe Esmolol Inj 1 mg per ml, 10 ml Inj 250 mg per ml, 10 ml Ethanol Spray 70% Ethyl Alcohol Gel 61.5% Ethyl Chloride Spray Etoposide Cap 50 mg Inj 20 mg per ml, 5 ml Fentanyl Patches 2.5 mg Patches 5 mg Ferrous Sulphate Tab long-acting 325 mg Filgrastim Inj 500 ug per 1.67 ml Flucloxacillin Cap 500 mg Inj 12 g Inj 4 g Inj 8 g Fludarabine Inj 1 mg Tab 10 mg Flumazenil Inj 100 ug per ml, 5 ml Flunitrazepam Inj 2 mg Fluorescein Inj 10% Fluorouracil Inj 25 mg per ml, 10 ml Inj 25 mg per ml, 100 ml Inj 25 mg per ml, 20 ml

0% 0% 0% 0% 0% 0% 0% 0% 0%

0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%

Friday, 17 October 2003

Page 6

---

Chemical Name

Formulation Name

Proposed DV Limit

Suggested DV Limit

Product specific comments

Fluorouracil Inj 50 mg per ml, 10 ml Inj 50 mg per ml, 20 ml Inj 50 mg per ml, 5 ml Inj 50 mg per ml, 50 ml Fluphenazine Decanoate Inj 100 mg per ml, 1 ml Flurbiprofen Eye drops 0.03% Fluticasone Aerosol 250 mcg per dose Aerosol inhaler 125 mcg per dose Folinic Acid Inj 10 mg per ml, 5 ml Inj 7.5 mg per ml, 2 ml Framycetin Sulphate Ear/Eye oint 0.5% Frusemide Infusion 10 mg per ml, 25 ml Inj 10 mg per ml, 2 ml Fusidic Acid Inj 500 mg sodium fusidate per 10 ml Gelofusine Inf 4%, 500 ml Gemcitabine Inj 1 g Inj 200 mg Gemeprost Pessary 1 mg Gentamicin Sulphate Inj 10 mg per ml, 2 ml Glutaraldehyde Soln 2% Glyceryl Trinitrate Inj 1 mg per ml, 5 ml Inj 1 mg per ml, 50 ml Glycine Inf 1.5%, 2000 ml Glycopyrrolate Inj 200 mcg per ml Goserelin Acetate Inj 10.8 mg Inj 3.6 mg Heparin Sodium Inj 1,000 iu per ml, 35 ml Inj 1,000 iu per ml, 5 ml Inj 25,000 iu per ml, 0.2 ml Inj 25,000 iu per ml, 5 ml Inj 5,000 iu per ml, 5 ml

0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%

Friday, 17 October 2003

Page 7

---

Chemical Name

Formulation Name

Proposed DV Limit

Suggested DV Limit

Product specific comments

Heparinised Saline Inj 100 iu per ml, 5 ml Hydrocortisone Inj 50 mg per ml, 2 ml Hydrocortisone with Cinchocaine Oint 5 mg with cinchocaine hydrochloride 5 mg per g Hyoscine N-Butylbromide Inj 20 mg 1 ml Idarubicin Cap 10 mg Ifosfamide Inj 1 g Inj 2 g Indinavir Cap 400 mg Iodine in Alcohol Soln 1% in 70% alcohol Iohexol Inj 300 mg per ml, 100 ml Inj 300 mg perml, 20 ml Inj 300 mg perml, 50 ml Ipratropium Bromide Aerosol inhaler, 20 mcg per dose Nebuliser soln, 500 mcg per 2 ml Irinotecan Inj 20 mg per ml, 2 ml Inj 20 mg per ml, 5 ml Iron-sucrose complex Inj 20 mg per ml, 5 ml Isoprenaline Inj 200 mcg per ml, 5 ml Isoprenaline Hydrochloride Inj 200 mcg per ml, 1 ml Itraconazole Cap 100 mg Ketamine Inj 100 mg per ml, 2 ml Labetalol Inj 5 mg per ml, 20 ml Lactulose Oral liq 10 g per 15 ml Lamivudine Tab 100mg Tab 150 mg Lamotrigine Tab dispersible 100 mg Lanolin Lotn anhydrous

0% 0% 0%

0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%

Friday, 17 October 2003

Page 8

---

Chemical Name

Formulation Name

Proposed DV Limit

Suggested DV Limit

Product specific comments

Leflunomide Tab 10 mg Leuprorelin Inj 11.25 mg Inj 3.75 mg Levodopa with Carbidopa Tab long-acting 200 mg with 50 mg carbidopa Levo-Noradrenaline Inj 1 mg per ml, 2 ml Lignocaine Gel 20 g Inj 10%, 50 ml Lignocaine and Adrenaline Inj 2%, 2.2 ml Lignocaine with Chlorhexidine Gel 2% with 0.05% chlorhexidine Lignocaine with Prilocaine Patch 2.5% Lignocaine with Prilocaine Hydrochloride Crm 2.5% with prilocaine hydrochloride 2.5% Linezolid Inj 2 mg per ml, 300 ml Tab 600 mg Lithium Carbonate Cap 250 mg lodixanol Inj 270 mg per ml, 100 ml Inj 270 mg per ml, 50 ml Loratidine Tab 10 mg Lorazepam Inj 4 mg per ml, 1 ml Magnesium Sulphate Inj 49.3%, 5 ml Medroxyprogesterone Acetate Inj 150 mg per ml 1 ml Meropenem Inj 1 g Inj 500 mg Mesalazine Tab long-acting 500 mg Mesna Inj 100 mg per ml, 10 ml Metaraminol Tartrate Inj 10 mg per ml, 1 ml Methacholine Chloride Nebuliser soln 100 mg Methohexital Sodium Inj 500 mg

0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%

Friday, 17 October 2003

Page 9

---

Chemical Name

Formulation Name

Proposed DV Limit

Suggested DV Limit

Product specific comments

Methotrexate Inj 1 g, 10 ml vial Inj 20 mg, 2 ml vial Methylene Blue Inj 10 mg per ml, 10 ml Methylprednisolone Inj 40 mg per ml Metoprolol Succinate Tab long-acting 47.5 mg Metoprolol Tartrate Inj 1 mg per ml 5 ml Metronidazole Suppos 1 g Miconazole Nitrate Powder 2% Mifepristone Tab 200 mg Milrinone Inj 1 mg per ml, 10 ml Mitozantrone Inj 2 mg per ml, 10 ml Monoxidil Tab 10 mg Moxifloxacin Inj 400 mg Nelfinavir Tab 250 mg Netilmicin Sulphate Inj 100 mg per ml, 1.5 ml Nevirapine Tab 200 mg Nimodipine Inj 0.2 mg per ml, 50 ml Tab 30 mg Norfloxacin Tab 400 mg Oily Phenol Inj 5%, 5 ml Oxaliplatin Inj 100 mg Inj 50 mg Oxandrolone Tab 2.5 mg Oxypentifylline Tab 400 mg Oxytocin Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 ug per ml, 1 ml Palivizumab Inj 100 mg

0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%

0%

Friday, 17 October 2003

Page 10

---

Chemical Name

Formulation Name

Proposed DV Limit

Suggested DV Limit

Product specific comments

Papaverine Hydrochloride Inj 12 mg per ml, 10 ml Paracetamol Tab 500 mg Paraffin Liquid White soft Yellow soft Pentamidine Inj 300 mg Pethidine Hydrochloride Inf 5 mg per ml, 100 ml Inj 10 mg per ml, 50 ml Inj 5 mg per ml, 10 ml Inj 5 mg per ml, 50 ml Inj 50 mg per ml, 1 ml Inj 50 mg per ml, 2 ml Phenobarbitone Inj 200 mg Phenol Inj 5% in almond oil Phenoxybenzine Inj 50 mg per ml, 2 ml Phenylephrine Minim eye drops 2.5% Phytomenadione Inj 10 mg per ml, 0.2 ml Piperacillin Inj 2 g Inj 4 g Piperacillin with Tazobactam Inj 2 g with tazobactum 250 mg Inj 4 g with tazobactum 500 mg Polyethylene Glycol with Sodium Sulphate Powder Potassium Chloride Tab 548 mg (14 m eq ) with chloride 285 mg ( 8 m eq ) effervescent Tab long-acting 600 mg Potassium Dihydrogen Phosphate Inj 1 mmol per ml, 10 ml Povidone Iodine Alcohol skin preparation 10% Antiseptic Soln 10% Prednisolone Sodium Phosphate Oral liq 5 mg per ml Prednisone Tab 20 mg Prochlorperazine Suppos 25 mg

0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%

Friday, 17 October 2003

Page 11

---

Chemical Name

Formulation Name

Proposed DV Limit

Suggested DV Limit

Product specific comments

Protamine Sulphate Inj 10 mg per ml, 5 ml Pyridostigmine Bromide Tab long-acting 180 mg Quinapril Tab 10 mg Tab 20 mg Tab 5 mg Ranitidine Hydrochloride Inj 25 mg per ml, 2 ml Rasburicase Inj 1.5 mg Remifentanil Inj 5 mg per ml Rifampicin Cap 300 mg Inj 600 mg Rocuronium Bromide Inj 10 mg per ml, 1 ml Inj 10 mg per ml, 5 ml Salbutamol Infusion 1 mg per ml, 5 ml Nebuliser soln, 1 mg per ml, 2.5 ml Nebuliser soln, 2 mg per ml, 2.5 ml Salbutamol with Ipratropium Bromide Aerosol inhaler, 100 mcg with ipratropium bromide 20 mcg per dose Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml vial Salmeterol Aerosal inhaler, 25 ug per dose Saquinavir Cap 200 mg Sertraline Tab 50 mg Silver Sulphadiazine Crm 1% Simvastatin Tab 10 mg Tab 20 mg Tab 40 mg Sincalide Inj 5 mcg Sodium Acid Phosphate Enema 16% with sodium phosphate 8% Sodium and Meglumine Diatrizoate Inj 76%, 100 ml Inj 76%, 50 ml Sodium Bicarbonate Inj 8.4% 10 ml

0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%

0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%

Friday, 17 October 2003

Page 12

---

Chemical Name

Formulation Name

Proposed DV Limit

Suggested DV Limit

Product specific comments

Sodium Citro-Tartrate Grans effervescent 4 g sachets Sodium Dichloroisocyanurate Tab effervescent 500 mg Sodium Hyaluronidate Inj 14 mg per ml Sodium Hypochlorite Soln Sodium Thiosulphate Inj 25%, 50 ml Teicoplanin Inj 400 mg Tenoxicam Inj 10 mg per ml, 4 ml Inj 20 mg Inj 20 mg per ml, 2 ml Thiamine Inj 100 mg per ml, 2 ml Thiopentone Inj 500 mg Ticaracillin with Potassium Clavulanate Inj 3 g with 100 mg potassium clavulanate Tirofiban Inj 250 mcg per ml, 50 ml Tobramycin Inj 40 mg per ml, 2 ml Tranexamic Acid Inj 100 mg per ml, 5 ml Tab 500 mg Tretinoin Cap 10 mg Triamcinolone Acetonide Inj 10 mg per ml, 1 ml Inj 10 mg per ml, 5 ml Inj 40 mg per ml, 1 ml Inj 40 mg per ml, 5 ml Tropicamide Eye drops 1% Minims 1% Urokinase Inj 10,000 iu Inj 100,000 iu Inj 500,000 iu Ursodiol Cap 300 mg Vancomycin Hydrochloride Cap 125 mg Inj 50 mg per ml, 10 ml Vasopressin Inj 20 iu per ml

0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%

Friday, 17 October 2003

Page 13

---

Chemical Name

Vecuronium

Formulation Name

Proposed DV Limit

Suggested DV Limit

Product specific comments

0% Inj 10 mg Vincristine Inj 1 mcg Vincristine Sulphate Inj 1 mg per ml, 2 ml Vinorelbine Inj 10 mg Inj 10 mg per ml, 5 ml Voriconzole Tab 200 mg Water for injection 100 ml 1000 ml Water for irrigation 1000 ml Xylometazoline Nasal spray 0.1% Zidovudine with Lamivudine Tab 300 mg with lamivudine 150 mg Zinc and Castor Oil Oint Zopiclone Tab 7.5 mg Zuclopenthixol Inj 50 mg per ml, 2 ml Tab 25 mg Zuclopenthixol acetate Acuphase 50mg/ml injection Zuclopenthixol Decanoate Inj 200 mg per ml 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%

Friday, 17 October 2003

Page 14